Timing of probiotic milk consumption during pregnancy and effects on the incidence of preeclampsia and preterm delivery: a prospective observational cohort study in Norway

Mahsa Nordqvist,1 Bo Jacobsson,2,3 Anne-Lise Brantsæter,4 Ronny Myhre,5 Staffan Nilsson,6 Verena Sengpiel1

ABSTRACT

Objectives To investigate whether the timing of probiotic milk intake before, during early or late pregnancy influences associations with preeclampsia and preterm delivery.

Design Population based prospective cohort study.

Setting Norway, between 1999 and 2008.

Participants 70149 singleton pregnancies resulting in live-born babies from the Norwegian Mother and Child Cohort Study (no chronic disease, answered questionnaires, no placenta previa/ cerclage/ serious malformation of fetus, first enrolment pregnancy). Only nulliparous women (n=37050) were included in the preeclampsia analysis. Both iatrogenic and spontaneous preterm delivery (between gestational weeks 22+0 and 36+6) with spontaneous term controls (between gestational weeks 39+0 and 40+6) were included in the preterm delivery analysis resulting in 34458 cases.

Main outcome measures Adjusted OR for preeclampsia and preterm delivery according to consumption of probiotic milk at three different time periods (before pregnancy, during early and late pregnancy).

Results Probiotic milk intake in late pregnancy (but not before or in early pregnancy) was significantly associated with lower preeclampsia risk (adjusted OR: 0.80 (95% CI 0.68 to 0.94) p-value: 0.007). Probiotic intake during early (but not before or during late pregnancy) was significantly associated with lower risk of preterm delivery (adjusted OR: 0.79 (0.64 to 0.97) p-value: 0.03).

Conclusions In this observational study, we found an association between timing of probiotic milk consumption during pregnancy and the incidence of the adverse pregnancy outcomes preeclampsia and preterm delivery. If future randomised controlled trials could establish a causal association between probiotics consumption and reduced risk of preeclampsia and preterm delivery, recommending probiotics would be a promising public health measure to reduce these adverse pregnancy outcomes.

BACKGROUND

Preeclampsia and preterm delivery are two major challenges in modern obstetrics. Preeclampsia is a multisystem disorder affecting 2%–8% of all pregnancies.1 Preterm delivery, defined by the WHO as birth occurring before 37 weeks of gestation, is the leading cause of perinatal mortality and a major cause of paediatric morbidity and disability.2 The rates of preterm delivery in Scandinavia, 5.6% to 6.4%, are among the lowest in the world.3 In the United States, however, the rate is as high as 9.6%.4

Maternal inflammatory response is a crucial part in the pathophysiology of these conditions.5–16 The pathogenesis of preeclampsia involves activation of the coagulation system and endothelial cell dysfunction.17 It is believed that this endothelial dysfunction is part of a wider maternal inflammatory response, present in normal pregnancy but exaggerated in preeclampsia.5 Increased inflammatory response seems to play a greater role especially in early-onset6 7 and severe8–10 preeclampsia. Preterm delivery is clinically divided into spontaneous preterm delivery, including preterm labour and preterm prelabor rupture of membranes, and iatrogenic preterm delivery. As with preeclampsia,
an increased inflammatory response seems to play a role in spontaneous preterm delivery. This is partly explained by microbial invasion of the amniotic cavity leading to activation of the innate immune system and increased production of prostaglandins, leading to intraterine contractility and increased risk of preterm labour. Additional inflammatory mediators influence the degradation of extracellular matrix in the fetal membranes, contributing to processes leading toward preterm prelabor rupture of membranes.\textsuperscript{11,12,14,16}

Modern obstetrics has not yet developed reliable methods to prevent or treat either of these conditions. Medical intervention in preeclampsia remains limited,\textsuperscript{18} although prophylactic aspirin treatment might be of importance.\textsuperscript{19,20} Interventions aimed at predicting and preventing spontaneous preterm delivery have also yielded limited success, although cervical length measurement and prophylactic progesterone treatment are promising.\textsuperscript{21,22}

Growing evidence suggests that maternal diet influences pregnancy outcome, for example dietary pattern characterised by high intake of vegetables, fruits, and vegetable oils, which is associated with reduced risk of preeclampsia and preterm delivery.\textsuperscript{23–26} Probiotics are defined as ‘live microorganisms, which, when administered in adequate amounts, confer a health benefit on the host’.\textsuperscript{27} It has been shown that orally ingested probiotics have the potential to colonise the vagina\textsuperscript{28} and normalise the bacterial flora in the lower genital tract.\textsuperscript{29} Probiotics may have an anti-inflammatory effect on lipopolysaccharide inflammatory response in human placental trophoblast cells.\textsuperscript{30,31} The anti-inflammatory effect of orally ingested probiotics has also been shown in vivo.\textsuperscript{32,33} Two previous studies in the Norwegian Mother and Child Cohort Study (MoBa) showed associations between intake of milk containing probiotics during the first half of pregnancy and reduced risk of preeclampsia and spontaneous preterm delivery.\textsuperscript{34,35} Since pregnancy is a time of rapid development and differentiation, the aim of this study was specifically to investigate whether there might be a certain time window before, during early or late pregnancy for a probiotic exposure effect on these two adverse pregnancy outcomes.

The women were asked to answer three questionnaires during pregnancy, at gestational week 15 (Questionnaire 1 (Q1)), 22 (Questionnaire 2 (Q2)) and 30 (Questionnaire 3 (Q3)). Q2 is a food frequency questionnaire (FFQ), whereas Q1 and Q3 are more general questionnaires covering health, exposures, lifestyle and other background factors. The records of the participating women are linked to the Medical Birth Registry of Norway (MBRN).\textsuperscript{36} This study is based on data from MoBa Q1, Q3 and the MBRN, in contrast to our previous studies where the exposure data was from Q2.\textsuperscript{34,35}

In MoBa, 98 725 women gave birth to live singleton babies. Of these 91 038 had answered both Q1 and Q3 and were eligible for inclusion in the study. After exclusion of women with chronic diseases or pregnancy complications (rheumatoid arthritis, chronic kidney disease, chronic hypertension, chronic heart disease, diabetes mellitus; types 1 and 2 and gestational diabetes, immunosuppression, epilepsy, asthma, placenta previa, cerclage, serious malformation), 70 149 pregnancies were included in the study. (Figure 1) Only a woman’s first enrolled pregnancy in MoBa was included.

**Exposure**

Q1\textsuperscript{39} and Q3\textsuperscript{40} contain questions about intake of two different milk products containing probiotic lactobacilli, in which consumption is defined in terms of ‘cups/glasses per day’, specified as 1 mug=2 cups, 0.5 litres=4 cups and 1.5 litres=12 cups. In Q1, the women were asked to report their consumption both prior to becoming pregnant and during pregnancy up until the time that the questionnaire was completed (on average around week 17), while Q3 (answered around week 30) asked about consumption from week 13 and until answering the questionnaire. The participant is defined as a probiotic consumer if she has written any number larger than zero, with no cut-off. The probiotic milk products were product A (Biola, all types, manufactured by Tine SA, Oslo.), containing *Lactobacillus acidophilus* (LA-5), *Bifidobacterium lactis* (Bb12), and *Lactobacillus rhamnosus GG* (LGG); and product B (Cultura, all types, manufactured by Tine SA, Oslo.), containing *Lactobacillus acidophilus* (LA-5) and *Bifidobacterium lactis* (Bb12). These were the only probiotic food items commonly available in Norwegian stores at the time of the study. The content of probiotic bacteria in these beverages is 10\textsuperscript{8} probiotic bacteria/mL according to the manufacturer. We did not include information regarding the use of probiotic supplements, as detailed assessment of dietary supplement use in MoBa\textsuperscript{41} showed that less than 0.5\% of the women reported use of supplements containing probiotic substances. The contribution of probiotics from dietary supplements was therefore considered negligible. Consumption prior to pregnancy reported in Q1 was defined as consumption before pregnancy, consumption reported during pregnancy in Q1 was defined as consumption during ‘early pregnancy’, while consumption reported in Q3 was defined as consumption during ‘late pregnancy’.

**METHODS**

**Population and study design**

MoBa is a prospective population-based pregnancy cohort study conducted by the Norwegian Institute of Public Health.\textsuperscript{36,37} Participants were recruited from all over Norway in 1999–2008. The women consented to participation in 41\% of the pregnancies. The cohort now includes 114 500 children, 95 200 mothers and 75 200 fathers. This study is based on version 6 of the quality-assured data files released for research in 2011. Informed consent was obtained from each MoBa participant on recruitment.
Outcome

The main outcomes were preeclampsia and preterm delivery in the current pregnancy, as registered in the MBRN. MBRN data contain information from the pregnancy and birth records and are based on forms filled in by doctors or midwives after birth. There are five boxes that can be ticked in the form connected to preeclampsia: hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome; eclampsia; early onset preeclampsia (diagnosed before 34 weeks); mild preeclampsia and severe preeclampsia. In this study, preeclampsia was diagnosed if any of these boxes were ticked. All pregnant women in Norway receive free prenatal care, including blood pressure measurement and urine analysis for protein at each visit. According to the Norwegian Society of Obstetrics and Gynaecology, the diagnostic criteria for preeclampsia are systolic blood pressure $\geq 140\text{ mmHg}$ and/or diastolic blood pressure $\geq 90\text{ mmHg}$ after 20 weeks’ gestation, combined with proteinuria $\geq 0.3$ grams per 24 hours or total protein/creatinine ratio $>0.3$ (or $>1$ on urine dipstick on at least two occasions). Severe preeclampsia is defined as blood pressure $\geq 160/110$, clinical signs such as epigastric pain, headache or other cerebral symptoms, rapidly developing oedema, lung oedema, eclampsia, proteinuria $\geq 3\text{ g/24 hours}$, oliguria $<500\text{ mL/24 hours}$, or HELLP. Severe preeclampsia in this study includes even HELLP, early onset preeclampsia and eclampsia. The registered preeclampsia diagnoses in the MBRN have recently been validated. As in our previous publication, only nulliparous women ($n=37050$) were included in the preeclampsia analysis.

Preterm delivery was defined as delivery between 22+0 and 36+6 weeks of gestation and spontaneous preterm delivery as delivery after either preterm labour or preterm prelabor rupture of membranes (PPROM). Gestational age was based on second-trimester ultrasound.
in 97.9% of the pregnancies and on last menstrual period in the remaining. Early (22+0–33+6) and late (34+0–36+6) spontaneous preterm delivery subgroups were analysed separately. As in our previous study, the comparison group in the preterm delivery analysis consisted of spontaneous term pregnancies delivered at gestational week 39+0–40+6 (35), resulting in a total of 34,458 women included in the preterm delivery analysis.

### Covariates

The logistic regression models were adjusted for known risk factors for preeclampsia and preterm delivery. The maternal characteristics and lifestyle variables initially examined as potential confounding variables were as follows: maternal age, height and educational level; parity; history of late miscarriage (after gestational week 12); history of preterm delivery (only for multiparous women in the preterm delivery analysis); pre-pregnancy body mass index (BMI); marital status; smoking and alcohol intake during current pregnancy; household income; fetal sex; in vitro fertilisation (IVF); intake of non-probiotic milk (ie, regular milk and sour milk, including kefir and yoghurt); and use of dietary supplements as a marker of health-conscious behaviour. Dietary supplement use was divided into three categories: ‘no supplement use’, ‘use of supplements without vitamin D’ and ‘use of supplements with vitamin D’, since it has been shown that supplementary vitamin D is associated with reduced risk of preeclampsia in previous studies. Self-reported pre-pregnancy weight and height were used to calculate BMI (weight (kg)/height (m²)). The variables BMI, maternal height, and history of late miscarriage were used as continuous variables. Maternal age at delivery was used as a continuous variable, except in table 1, where it was divided into six categories (<19 years, 20–24 years, 25–29 years, 30–34 years, 35–39 years, ≥40 years). Smoking (categorised yes/no) was self-reported in Q1 and has been validated with plasma cotinine as the reference measure. Parity (categorised in 0, 1, 2, and 3+para) was based on combined information from the MBRN and MoBa. Self-reported maternal educational level was divided into three categories (≤12 years, 13–16 years, ≥17 years.) Self-reported maternal and paternal annual incomes were divided into three categories (both have income <300,000 Norwegian crowns, one of them has income ≥300,000 NOK, both have income ≥300,000 NOK). Paternal sex was adjusted for due to findings, reported by Yeganegi et al, of a significant sex difference in inflammatory response to probiotics. First-trimester smoking, dietary supplement use, alcohol consumption, non-probiotic milk/yoghurt consumption and IVF were registered as yes or no. History of preterm delivery was categorised into yes, no, and nulliparous. Maternal age at delivery, history of preterm delivery, IVF, fetal sex and history of late miscarriage (12–24 weeks) were based on MBRN information. Maternal intake of non-probiotic milk (ie, regular milk and sour milk, including kefir and yoghurt) and alcohol consumption were reported in Q1 and Q3. Dietary supplement use was based on Q1.

### Statistical methods

Intake of probiotic milk in relation to maternal characteristics was examined using Pearson’s χ², while mean intake of probiotic milk according to maternal characteristics was examined using the Kruskal Wallis test. We estimated adjusted odds ratios (aOR) for the association between intake of probiotic milk (as categorised variables) and preeclampsia and preterm delivery using multiple logistic regression models with exposure at all three periods and covariates in the model. In categorical variables, missing data were given a category of their own. In a sensitivity analysis, missing values regarding food/beverage frequencies were classified as non consumers. The significance of exposure at each period as well as an overall significance of the null hypothesis of no impact of intake at any of the three periods was analysed. Preeclampsia and preterm delivery, including subtypes of both, were examined as separate outcome variables. Confounding variables were included in the final model if the covariate was associated with the exposure at P<0.05 (see table 1) or a priori (if there was a strong theoretical or clinical reason for keeping them in the model). The significance level was set at 5% (2 tailed) and all analyses were performed with SPSS version 24.

### Patient involvement

Patients were not involved in the design and conduct of this study.

### RESULTS

#### Probiotic milk consumption in the study population

Consumption of probiotic milk in the whole study population (n=70,149) before pregnancy was reported by 6502 (23.3%) of the women, (mean 1.56 cups/day among consumers), during early pregnancy by 11,221 (37.6%) women, (mean 1.60 cups/day among consumers), and during late pregnancy by 12,784 (32.2%) women, (mean 1.51 cups/day among consumers). As illustrated in figure 2, a substantial part of the study population consumed probiotic milk during more than one time period.

Intake of probiotic milk according to maternal characteristics is presented in table 1. Intake of probiotic milk was more common in women who were older, primiparous, had BMI <25, did not smoke, used dietary supplements, consumed non-probiotic yoghurt, and had higher educational levels and family income. Alcohol intake during pregnancy was more common among probiotic consumers.

#### Probiotic milk consumption and preeclampsia

Among the 37,050 nulliparous women included in the preeclampsia analysis, preeclampsia was diagnosed in 1851 (5.0%), including 550 cases of severe preeclampsia. Intake of probiotic milk during late pregnancy was significantly associated with a lower risk of preeclampsia (aOR: 0.80 (95% CI: 0.64 to 0.94)), while there was no significant
Table 1  Intake of probiotics in relation to maternal characteristics in 70 149 pregnancies

| Maternal characteristics          | Non consumers | Consumers* | P value† | Mean intake of probiotics among probiotic consumers‡ |
|-----------------------------------|---------------|------------|----------|-------------------------------------------------|
|                                  | n (%)         | n (%)      |          | cups/day (SD)                                   |
| All ¶                             | 29 770        | 17 493     |          | 1.50 (1.1)                                      |
| Maternal age                      |               |            |          |                                                 |
| <19 y                             | 368 (1.2)     | 93 (0.5)   | <0.001   | 2.25 (2.0)                                      |
| 20–24 y                           | 3445 (11.6)   | 1530 (8.7) |          | 1.66 (1.4)                                      |
| 25–29 y                           | 10 603 (35.6) | 6056 (34.6)|          | 1.54 (1.2)                                      |
| 30–34 y                           | 11 013 (37.0) | 6730 (38.5)|          | 1.50 (1.1)                                      |
| 35–39 y                           | 3900 (13.1)   | 2711 (15.5)|          | 1.49 (1.0)                                      |
| >40 y                             | 441 (1.5)     | 373 (2.1)  |          | 1.53 (1.2)                                      |
| Parity                            |               |            |          |                                                 |
| 0                                | 15 588 (52.4) | 10 713 (61.2)| < 0.001 | 1.53 (1.1)                                      | 0.20 |
| 1                                | 9231 (31.0)   | 4458 (25.5) |          | 1.53 (1.3)                                      |
| 2                                | 4042 (13.6)   | 1893 (10.8)|          | 1.53 (1.0)                                      |
| ≥3                               | 888 (3.0)     | 417 (2.4)  |          | 1.59 (1.1)                                      |
| Missing data                      | 21 (0.1)      | 12 (0.1)   | 1.67 (1.6) |                                                 |
| Previous spontaneous abortion     |               |            |          |                                                 |
| >12 – 21 (+ 6 d) wks              |               |            |          |                                                 |
| No history                        | 24 270 (81.5)| 14 033 (80.2)| <0.001 | 1.53 (1.2)                                      | 0.96 |
| Yes history                       | 702 (2.4)     | 386 (2.2)  |          | 1.52 (1.0)                                      |
| Missing data                      | 4798 (16.1)   | 3074 (17.6)|          | 1.53 (1.1)                                      |
| History of preterm delivery       |               |            |          |                                                 |
| No history                        | 13 179 (44.3)| 6286 (35.9)| <0.001   | 1.53 (1.3)                                      | 0.21 |
| Nulliparous                       | 15 586 (52.4)| 10 712 (61.2)|          | 1.53 (1.1)                                      |
| Yes history                       | 1005 (3.4)    | 495 (2.8)  |          | 1.47 (0.8)                                      |
| BMI before pregnancy              |               |            |          |                                                 |
| <18.5 kg/m²                       | 866 (2.9)     | 535 (3.1)  | <0.001   | 1.59 (1.1)                                      | 0.30 |
| ≥18.5 to<25 kg/m²                 | 18 694 (62.8)| 12 233 (69.9)|          | 1.52 (1.1)                                      |
| ≥25 to<30 kg/m²                   | 6515 (21.9)   | 3227 (18.4)|          | 1.56 (1.1)                                      |
| ≥30 to<35 kg/m²                   | 2135 (7.2)    | 843 (4.8)  |          | 1.54 (1.1)                                      |
| ≥35 kg/m²                         | 832 (2.8)     | 257 (1.5)  |          | 1.64 (1.6)                                      |
| Missing data                      | 728 (2.4)     | 398 (2.3)  |          | 1.50 (1.0)                                      |
| Marital status                    |               |            |          |                                                 |
| Married/cohabiting                | 28 650 (96.2)| 16 873 (96.5)| <0.001 | 1.52 (1.1)                                      | <0.001 |
| Not married/cohabiting            | 1120 (3.8)    | 620 (3.5)  |          | 1.75 (1.2)                                      |
| Smoking during pregnancy          |               |            |          |                                                 |
| No                                | 26 753 (89.9)| 16 214 (92.7)| <0.001 | 1.52 (1.1)                                      | <0.001 |
| Yes                               | 2686 (9.0)    | 1027 (5.9) |          | 1.73 (1.4)                                      |
| Missing data                      | 331 (1.1)     | 252 (1.4)  |          | 1.61 (1.0)                                      |
| Alcohol intake during pregnancy   |               |            |          |                                                 |
| No                                | 24 907 (83.7)| 13 965 (79.8)| <0.001 | 1.53 (1.2)                                      | 0.92 |
| Yes                               | 2694 (9.0)    | 2031 (11.6)|          | 1.47 (0.9)                                      |
| Missing data                      | 2169 (7.3)    | 21 497 (8.6)|          | 1.65 (1.2)                                      |
| Educational level                 |               |            |          |                                                 |
| ≤12 y                             | 9263 (31.1)   | 4088 (23.4)| <0.001   | 1.73 (1.5)                                      | <0.001 |

Continued
association with pre-pregnancy probiotic milk consumption and consumption during early pregnancy. (table 2)

When the subtypes mild and severe pre eclampsia were examined separately, a statistically significant association was only found for probiotic milk consumption during late pregnancy and severe preeclampsia (aOR: 0.68 (0.50 to 0.92)). (table 2) We found no significant dose response effect when consumption was divided into 0 cups/day, one cup/day and ≥2 cups/day.

When the two products where analysed in the same logistic regression model, no statistical difference could be found: Product A: late pregnancy: aOR: 0.80 (0.67 to 0.97); Product B: late pregnancy: aOR: 0.80 (0.63 to 0.99). However, there was a substantial consumption overlap between the two products. Probiotic milk products A and B were the only probiotic products widely available in Norway until 2007, when other probiotic products were introduced on the Norwegian market. Sensitivity analyses excluding births after 2007 resulted in similar results as for the full sample (late pregnancy: aOR: 0.82 (0.68 to 0.98)). Sensitivity analysis, with missing values in variables regarding food/beverage frequency recoded as non consumers, resulted in similar results as when missing values were coded as a separate category: preeclampisa and probiotic consumption in late pregnancy: aOR: 0.79 (0.69 to 0.92).

### Probiotic consumption and preterm delivery

In the 34,458 women included in the preterm delivery analysis, preterm delivery occurred in 2858 cases, of which 1795 were spontaneous preterm deliveries and 1063 were iatrogenic preterm deliveries. There was a significant association between consumption of probiotic milk during early pregnancy and reduced risk of preterm delivery (aOR: 0.79 (0.64 to 0.97)), while there was no significant association with pre-pregnancy probiotic milk consumption and consumption during late pregnancy (table 3). In subgroup analysis for early (gestational weeks 22+0–33+6) and late preterm delivery (gestational weeks 34+0–36+6), a significant association was found for probiotic consumption during early pregnancy and lower risk of late preterm delivery (aOR: 0.73 (0.57 to 0.92)) (table 3).

### Table 1

| Non consumers | Consumers* | P value† | Mean intake of probiotics among probiotic consumers‡ |
|---------------|------------|----------|------------------------------------------------------|
| n (%)         | n (%)      |          | cups/day (SD)                                       |
| 13–16 y       | 12,806 (43.0) | 7407 (42.3) | 1.50 (1.0) |
| ≥17 y         | 7117 (23.9) | 5629 (32.2) | 1.43 (0.9) |
| Missing data  | 584 (2.0) | 368 (2.1) | 1.59 (1.7) |

Annual income for participant and partner

|                      | n (%)          | n (%)         | P value§ |
|----------------------|----------------|---------------|----------|
| Both have incomes< NOK 300 000 | 8892 (29.9) | 4181 (23.9) | <0.001   |
| One has income ≥ NOK 300 000 | 12,248 (41.1) | 6870 (39.3) | 1.52 (1.1) |
| Both have incomes ≥ NOK 300 000 | 7855 (26.4) | 5993 (34.3) | 1.46 (1.0) |
| Missing data         | 775 (2.6)     | 449 (2.6)     | 1.57 (1.0) |

Dietary supplements

|                      | n (%)          | n (%)         | P value‡ |
|----------------------|----------------|---------------|----------|
| Yes, without vitamin D | 1795 (6.0)     | 1301 (7.4)    | <0.001   |
| Yes, with vitamin D   | 2782 (9.3)     | 2249 (12.9)   | 1.52 (1.1) |
| No                   | 25,193 (84.6)  | 13,943 (79.7) | 1.53 (1.1) |

Non probiotic milk intake

|                      | n (%)          | n (%)         | P value‡ |
|----------------------|----------------|---------------|----------|
| Yes                  | 23,585 (79.2)  | 13,660 (78.1) | <0.001   |
| No                   | 6158 (20.7)    | 2229 (12.7)   | 1.55 (1.1) |
| Missing data         | 27 (0.1)       | 1604 (9.2)    | 1.57 (1.3) |

Non probiotic yoghurt intake

|                      | n (%)          | n (%)         | P value‡ |
|----------------------|----------------|---------------|----------|
| Yes                  | 7507 (25.2)    | 5794 (33.1)   | <0.001   |
| No                   | 22,159 (74.4)  | 6916 (39.5)   | 1.51 (1.1) |
| Missing data         | 104 (0.3)      | 4783 (27.3)   | 1.47 (1.1) |

*Consumer is defined as a woman with consumption at any time point (before, during early and/or late pregnancy).
†Pearson’s χ² asymptotic 2-sided test of intake frequencies in groups.
‡Probiotic intake during early pregnancy.
§Kruskal-Wallis test.
¶Missing data regarding probiotic consumption n(%): 22,886 (32.6)

NOK, Norwegian Krone.

Nordqvist M, et al. BMJ Open 2018;8:e018021. doi:10.1136/bmjopen-2017-018021
When preterm delivery was divided into spontaneous and iatrogenic preterm delivery, association was only found for probiotic consumption during early pregnancy and lower risk of spontaneous preterm delivery (aOR: 0.74 (0.57 to 0.96)) (table 3). Four hundred and thirty of the 1063 cases of iatrogenic preterm delivery had a preeclampsia diagnosis. We found similar results as for the whole group when the group of spontaneous preterm delivery was divided into early and late preterm delivery. (see online supplemental table 1)

We found no significant dose response effect when consumption was divided into 0 cups/day, one cup/day and ≥2 cups/day. No significant difference was found between the two products when analysed in the same logistic regression model (data not shown), however there was a substantial consumption overlap between the two products.

Sensitivity analyses excluding births after 2007 resulted in similar results as for the full sample (early pregnancy: aOR: 0.79 (0.66 to 0.93)). Sensitivity analysis with missing values in variables regarding food/beverage frequency recoded as non consumers, resulted in similar results as when missing values were coded as a separate category: preterm delivery and probiotic consumption in early pregnancy: aOR: 0.79 (0.66 to 0.93).

**DISCUSSION**

We investigated the association between timing (before, early and late pregnancy) of probiotic milk consumption and the risk of developing preeclampsia or preterm delivery. Our results showed that probiotic milk intake during late pregnancy (but not before or in early pregnancy) was associated with reduced risk of preeclampsia, and that intake during early pregnancy (but not before or in late pregnancy) was associated with reduced risk of preterm delivery. No dose response effect was found. In this study we were not able to separate the impact of the specific probiotic products. When analysing subgroups,

Table 2 Intake of probiotics before and during pregnancy and risk of preeclampsia in nulliparous women, n=37 050

| Cases (controls)* | Adjusted OR (CI)† | P value |
|------------------|-------------------|--------|
| Preeclampsia all |                   |        |
| Overall          | 1.06 (0.83 to 1.35)| 0.65   |
| Before           | 1.10 (0.83 to 1.35)| 0.65   |
| Early            | 0.90 (0.72 to 1.12)| 0.35   |
| Late             | 0.80 (0.68 to 0.94)| 0.007  |
| Preeclampsia mild|                   |        |
| Overall          | 1.05 (0.77 to 1.43)| 0.77   |
| Before           | 1.05 (0.77 to 1.43)| 0.77   |
| Early            | 1.0 (0.75 to 1.32 )| 0.98   |
| Late             | 0.86 (0.70 to 1.06)| 0.15   |
| Preeclampsia severe |               |        |
| Overall          | 1.00 (0.63 to 1.60)| 0.99   |
| Before           | 1.00 (0.63 to 1.60)| 0.99   |
| Early            | 0.82 (0.54 to 1.25)| 0.36   |
| Late             | 0.68 (0.50 to 0.92)| 0.01   |

*The sum of mild and severe does not add up to all due to the fact that some were unspecified.
†Adjusted for maternal age, height and educational level; pre-pregnancy body mass index (BMI); marital status; smoking, alcohol and intake of non-probiotic milk products during current pregnancy; family income; fetal sex; in vitro fertilisation (IVF) and intake of dietary supplements (with and without vitamin D).
Table 3

| Intake of probiotics before and during pregnancy and risk of preterm delivery in singleton pregnancies, n=34,458 |
|----------------------------------------------------------|
| Preterm delivery (full term) | Adjusted OR (CI)* | P value |
|-----------------------------|------------------|---------|
| Preterm delivery all        | 2455 (26 910)    |         |
| Overall                     | –                | 0.08    |
| Before                      | 1.16 (0.92 to 1.45) | 0.21    |
| Early                       | 0.79 (0.64 to 0.97) | 0.03    |
| Late                        | 0.99 (0.85 to 1.14) | 0.85    |
| Preterm delivery early      | 498 (26 910)     |         |
| Overall                     | –                | 0.76    |
| Before                      | 0.86 (0.55 to 1.37) | 0.52    |
| Early                       | 1.07 (0.70 to 1.62) | 0.76    |
| Late                        | 0.94 (0.69 to 1.28) | 0.69    |
| Preterm delivery late       | 1957 (26 910)    |         |
| Overall                     | –                | 0.05    |
| Before                      | 1.25 (0.97 to 1.60) | 0.08    |
| Early                       | 0.73 (0.57 to 0.92) | 0.008   |
| Late                        | 0.98 (0.85 to 1.13) | 0.78    |
| Spontaneous Preterm delivery| 1536 (26 910)    |         |
| Overall                     | –                | 0.03    |
| Before                      | 1.23 (0.94 to 1.62) | 0.14    |
| Early                       | 0.74 (0.57 to 0.96) | 0.02    |
| Late                        | 0.97 (0.67 to 1.40) | 0.85    |
| Iatrogenic Preterm delivery | 919 (26 910)     |         |
| Overall                     | –                | 0.76    |
| Before                      | 1.02 (0.71 to 1.47) | 0.90    |
| Early                       | 0.90 (0.64 to 1.25) | 0.52    |
| Late                        | 1.06 (0.85 to 1.33) | 0.60    |

*Adjusted for maternal age, height and educational level; parity; history of late miscarriage; history of preterm delivery (for multiparous only); pre-pregnant body mass index (BMI); marital status; smoking, alcohol, and intake of non-probiotic milk products during current pregnancy; family income; fetal sex; in vitro fertilisation (IVF) and intake of dietary supplements (with and without vitamin D).

we found a stronger association between probiotic milk intake and reduced risk of spontaneous and late preterm delivery.

We were surprised to find a lack of association between probiotic intake and iatrogenic preterm delivery, since an important reason for selecting pregnancies for induction in preterm pregnancy is severe preeclampsia and intrauterine growth restriction, which can be a cause of placental dysfunction in preeclampsia. A substantial part (450 (40%)) of cases with iatrogenic preterm delivery had in fact a preeclampsia diagnosis. However, looking at the number of cases of iatrogenic preterm delivery included in the regression (n=919), a lack of power could explain the lack of association.

The biological hypothesis behind this work was that probiotics might have an effect on the inflammatory cascade following a possible infection, leading to preterm delivery. Therefore, we would have expected to find a stronger association with early preterm delivery since infection is thought to be the major cause in early preterm delivery. The non-significant finding could however be due to lack of power since there were only 498 cases of early preterm delivery. Further, it must be recognised that the preterm parturition syndrome has different aetiologies and the potential role of probiotic bacteria in preventing preterm delivery could therefore not be expected to be the same for all cases.

The two previous MoBa studies indicating a protective effect of probiotic milk on preeclampsia and spontaneous preterm delivery were based on the FFQ answered in mid pregnancy. As specific environmental factors such as infection (eg, congenital rubella syndrome after infection during the first trimester) or medication (eg, specific birth defects after thalidomid medication in certain pregnancy weeks) might influence pregnancy outcome during a certain time period, with no effect during other periods of pregnancy, it was pertinent to follow-up the results to investigate a potential importance of timing. Investigating whether probiotics have their effect already during placentation or later during pregnancy, for example after onset of preeclampsia symptoms, might also be a helpful guide when investigating the mechanisms behind these adverse outcomes. Previous publications in the MoBa cohort and other cohorts demonstrate that women tend to adopt a more health-conscious diet when they become pregnant, that is, reduced intake of coffee, alcohol and sweet beverages, and increased intake of fruit and vegetables. The same pattern was seen for probiotics consumption, which increased during early pregnancy but decreased slightly during late pregnancy, but still remained higher than before pregnancy. This additionally highlights the need to study consumption at different time-points.

There is evidence that a wider maternal inflammatory response plays a role in the pathogenesis of preeclampsia. Steinborn et al showed that preeclampsia and preterm delivery are characterised by changes in the composition of regulatory T cell, decreasing their suppressive activity. Increased inflammatory response seems to play a greater role especially in severe preeclampsia, which might explain our finding of a significant association only between probiotic intake and severe preeclampsia. These results are also in alignment with our previous study. Our biological hypothesis included both a local probiotics-mediated effect and an effect on the systemic
inflammatory response. In vitro studies have shown that probiotics (Lactobacillus rhamnosus GR-I and LGG) may have an anti-inflammatory effect on LPS inflammatory response in human placental trophoblast cells. It has been shown that daily prophylactic intake of probiotics (0.5×10⁷ Bifidobacterium longum, 0.5×10⁷ Lactobacillus bulgaricus, and 0.5×10⁷ Streptococcus thermophilus) could reduce the deviated T-helper cell T-helper 1 (Th1)/T-helper 2 (Th2) response induced by severe traumatic brain injury resulting in a lower rate of nosocomial infections. These results are very interesting since it is known that during pregnancy, the mother’s immune system changes from Th1-dominated cellular immunity to Th2-dominated humoral immunity in order to accept the fetal ‘semi-allograft’. In a randomised, double blind, placebo-controlled trial it was shown that maternal probiotics supplementation (10⁹ Bifidobacterium lactis alone or in combination with 10⁹ Lactobacillus rhamnosus GG) significantly modulated the expression of toll-like receptor (TLR)-related genes both in the placenta and in the oral microbiome, which resemble the oral more than the vaginal microbiome, is another interesting finding in this regard. Further, periodontal disease and the oral microbiome have been shown to be linked to preterm birth and preeclampsia.

Probiotics have the potential to impact the pathophysiological processes involved in hypertension, inflammation, renal function and diabetes. Various microorganisms have been found to possess such properties, although Lactobacillus and Bifidobacterium are the most common probiotic food adjuvants. It has been shown that probiotics (1.68×10¹⁰ L. rhamnosus CFUs per ml, 3.2×10¹⁰ L. casei, and 5.2×10¹⁰ L. acidophilus) modulate human gene expression in the gut lining, acting similarly to drugs that target high blood pressure. Clinical intervention trials have shown a reduction of blood pressure in non-pregnant individuals with probiotics intake (two strains of Streptococcus thermophilus (CFU 10×10⁵) and two strains of Lactobacillus acidophilus (CFU 2×10⁵) in one of the products and one strain of Enterococcus faecium (human species) (CFU 6×10⁵) and two strains of Streptococcus thermophilus (CFU 1×10⁶) in the other product). It could thus be hypothesised that probiotics might reduce the risk of preeclampsia by modulating blood pressure. This might explain our finding of a stronger association between probiotics consumption and preeclampsia, when probiotics are consumed during late pregnancy.

**Strengths and limitations**

The main strength is the large sample size and the link to the MBRN. MoBa is a pregnancy cohort with participants from both urban and rural regions, of different ages and socioeconomic groups and with a wide range of probiotics intake frequencies. The participation rate is 40.6%. Self-selection bias has been investigated, showing that single women under the age of 25 are underrepresented in MoBa. However, differences regarding preterm delivery incidence were minor and no differences in preeclampsia incidence were found. No bias was found in eight selected exposure-outcome associations. The questionnaires were filled in before delivery, avoiding confounding by retrospective responses. It is, however, difficult to obtain a true picture of dietary intake from a questionnaire. Questions about food answered in early pregnancy are especially challenging since many women experience changes in appetite. Another strength in the current study is that we have information about ‘typical’ consumption both before pregnancy and during early and late pregnancy, in contrast to a randomised controlled trial setting where the consumption is strictly defined by the study protocol. Probiotics are freely available and becoming more and more common as adjuvants on the food market. As shown, women continue to consume probiotics during pregnancy, emphasising the importance to investigate possible pregnancy-effects of the ‘typical’ consumption at any timing before or during pregnancy. Furthermore, we had access to information about lifestyle, allowing adjustment for potential health-conscious behaviour. However, although we adjusted for a number of confounding variables, including education and income which are the most important markers of socioeconomic position in Norway, unmeasured confounding cannot be ruled out.

Another strength is that the women reported whether their supplement contained vitamin D or not, which allowed us to adjust for intake of vitamin D, since studies have shown that vitamin D may be related to a lower risk for preeclampsia. None of the two probiotic milk products contained any added vitamin D during 1999–2008, ruling out that associations with the probiotic products could in fact be due to vitamin D.

Until 2007, the two Norwegian-produced probiotic milk products assessed in the MoBa questionnaires were the only probiotic food products commonly available on the Norwegian market, which is why we performed a sensitivity analysis excluding births after 2007. This did however not change the results. Still, women recruited to the study during years 2005–2008 may have consumed probiotic products other than the two assessed in these questionnaires. It is possible that some probiotic consumers have been classified as non-consumers in case they consumed probiotics from other sources. Another source of misclassification is that sour milk was included in ‘non-probiotic milk’. This misclassification of the exposure would most likely contribute to attenuation of a potential association with the outcomes studied.

Previous studies on probiotics have evaluated the health effect of different products containing various probiotic strains. Our study setting did not allow to evaluate certain strains of probiotics who may have an effect on these two adverse pregnancy outcomes, or at which daily
dose and dose regime. The main difference between the two probiotic products in this study was the presence of LGG. However, due to a substantial consumption overlap, we were not able to separate the impact of the specific probiotic products in this study. These results should however only imply the need for further studies, especially since there are earlier studies, showing the potential anti-inflammatory effect of Lactobacillus rhamnosus both in vitro and in vivo.30 31 33 70 Yang et al have indeed shown promising results where supernatant (bacteriocin) of Lactobacillus rhamnosus GR-1 attenuated the LPS-induced inflammation and preterm birth in the mouse model.70 In a recent prospective randomised trial in women with PPROM, vaginal probiotics (1×10^8 Lactobacillus rhamnosus and L. gasseri) as an adjunct to antibiotic prophylaxis were shown to prolong the latency period until delivery and improved the perinatal outcome.71 The probiotic consumers in our study consumed a mean dose of around 1.5 cups per day. This is equivalent to a consumption of at least 188 mL per day, and a probiotic dose of 1.9×10^10 (Bb12, LA-5 and LGG in product A and Bb12 and LA-5 in product B) according to the manufacturer. Strain viability during the product shelf life and its survival and pharmacokinetics in the gastrointestinal tract are important aspects that could not be analysed within the limits of our study. However, probiotic bacteria in commercial milk products have been shown to exhibit a high survival rate in the whole gastrointestinal tract.72 73

CONCLUSION

Probiotics might have a protective effect against adverse pregnancy outcomes and timing of probiotic intake might be relevant. Intake of probiotic milk during late pregnancy was associated with decreased risk of preeclampsia, and intake during early pregnancy was associated with decreased risk of preterm delivery. However, this observational study cannot establish causality and the pathophysiological effect of probiotics on the maternal inflammatory response must be studied in more detail, including strain-/*species-specific randomised controlled trials. If future randomised controlled studies support a protective effect of probiotics consumption on reduced risk of preeclampsia and preterm delivery, recommending probiotics consumption would be a promising public health measure to prevent these adverse pregnancy outcomes.

Acknowledgements

We are grateful to all the participating families in Norway who take part in this on-going cohort study. Bo Jacobsson received grants from the Norwegian Research Council (FUGE 183220/S10, FRIMEDKLI-05 ES236011), the Jane and Dan Olsson Foundations, the Swedish Medical Society (SLS 2008-21198) and Swedish government grants to researchers in the public health service (ALFGG-2863, ALFGG-11522). Payment of article - processing charges for this paper was received by Bo Jacobsson and covered by ahtigrensa University Hospital, Sahlgrenska Academy, Gothenburg, Sweden (ALFGG-426411). We would also like to acknowledge Jonas Bacelis, Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, for supporting us with the statistical analysis. All authors are independent from funders.

Contributors

All the authors participated in the planning and conduct of this study and approved the final version. MN, SN and VS analyzed the data. MN, VS, ALB, BJ, RM, SN contributed to interpretation of results and writing the paper. MN wrote the first draft of the manuscript. MN, BJ, VS, ALB, RM, and SN revised several versions of this manuscript. MN is the guarantor.

Funding

The Norwegian Mother and Child Cohort Study was supported by the Norwegian Ministry of Health and Care Services and the Ministry of Education and Research, NIH/NIEHS (contract no N01-ES-75558), NIH/NINDS (grant no.1 U01 NS 047537-01 and grant no.2 U01 NS 047537-06A1).

Competing interests

None declared.

Ethics approval

The present study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving human subjects were approved by the Regional Committee for Ethics in Medical Research in South-Eastern Norway (S-95113 and S-97045) and the Norwegian Data Inspectorate. This specific project was approved by The Regional Committee for Medical and Health Research Ethics South East (REK/S-06075a (2010/2683). All MoBa participants provided written informed consent before enrolment into the study.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data sharing statement

No additional data available.

Open Access

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

1. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365:785–99.
2. Committee WE. The prevention of perinatal mortality and morbidity. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1970;457:1–60.
3. Morken NH, Vogel I, Kallen K, et al. Reference population for international comparisons and time trend surveillance of preterm delivery proportions in three countries. BMC Womens Health 2008;8:16.
4. Hamilton BE, Martin JA, Osterman MJ. Births: preliminary data for 2015. Hyattsville, MD: National Center for Health Statistics, 2016.
5. James JL, Whitney GS, Cartwright JE. Pre-eclampsia: fitting together the placental, immune and cardiovascular pieces. J Pathol 2010;221:363–78.
6. Goswami D, Tandanetta DS, Magee LA, et al. Excess syncytiotrophoblast microparticle shedding is a feature of early-onset pre-eclampsia, but not normotensive intrauterine growth restriction. Placenta 2006;27:56–61.
7. von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy 2003;22:143–8.
8. Hu W, Wang H, Wang Z, et al. Elevated serum levels of interleukin-15 and interleukin-16 in preeclampsia. J Reprod Immunol 2007;73:166–71.
9. Miellembakk JR, Aukrust P, Hestdal K, et al. Chemokines and leukocyte activation in the fetal circulation during preeclampsia. Hypertension 2001;38:394–9.
10. Cudich D, Lee RV. The pathophysiology of pre-eclampsia: current clinical concepts. J Obstet Gynaecol 2009;29:576–82.

Author affiliations

1Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Sweden
2Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden
3Department of Genetics and Bioinformatics, Domain of Health Data and Digitalisation, Institute of Public Health, Oslo, Norway
4Department of Environmental Exposure and Epidemiology, Domain of Infection Control, Environment and Health, Norwegian Institute of Public Health, Oslo, Norway
5Department of Genetics and Bioinformatics, Domain of Health Data and Digitalisation, Norwegian Institute of Public Health, Oslo, Norway
6Mathematical Sciences, Chalmers University of Technology, Gothenburg, Sweden
7Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Sweden
11. McGregor JA, French JL, Richter R, et al. Antenatal microbiological and maternal risk factors associated with prematurity. *Am J Obstet Gynecol* 1990;163(5 Pt 1):1465–73.

12. Menon R, Fortunato SJ. Infection and the role of inflammation in preterm prelabour rupture of the membranes. *Best Pract Res Clin Obstet Gynaecol* 2007;21:467–78.

13. Romero R, Espinoza J, Kusanovic JP, et al. The preterm parturition syndrome. *BJOG* 2006;113(Suppl 3):17–42.

14. Jacobsson B, Mattsby-Baltzer I, Andersch B, et al. Microbial invasion and cytokine response in amniotic fluid in a Swedish population of women with preterm prelabour rupture of membranes. *Acta Obstet Gynecol Scand* 2003;82:423–31.

15. Goldenberg RL, Hauth JC, Andrews WW. Intrauterine infection and preterm delivery. *N Engl J Med* 2000;342:1500–7.

16. Romero R, Espinoza J, Chaiworapongsa T, et al. Infection and prematurity and the role of preventive strategies. *Semin Reprod Med* 2002;20:279–94.

17. Roberts JM. Preeclampsia: what we know and what we do not know. *Semin Perinatol* 2000;24:24–6.

18. Cindrova-Davies T. The therapeutic potential of antioxidants, ER chaperones, NO and H2S donors, and statins for treatment of preeclampsia. *Front Pharmacol* 2014;5:119.

19. Roibege S, Nicolaiades K, Demers S, et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. *Am J Obstet Gynecol* 2017;216:110–20.

20. Roibege S, Demers S, Nicolaiades KH, et al. Prevention of preeclampsia by low-molecular-weight heparin in addition to aspirin: a meta-analysis. *Ultrasound Obstet Gynecol* 2016;47:548–53.

21. Lockwood CJ. Predicting premature delivery--no easy task. *N Engl J Med* 2002;346:282–4.

22. Fonseca EB, Celik E, Parra M, et al. Progesterone and the risk of preterm birth among women with a short cervix. *N Engl J Med* 2007;357:462–9.

23. Shapira N. Prenatal nutrition: a critical window of opportunity for mother and child. *Womens Health* 2008;4:639–56.

24. Englund-Ögge L, Brantsaeter AL, Sengpiel V, et al. Maternal dietary patterns and preterm delivery: results from large prospective cohort study. *BMJ* 2014;348:g1446.

25. Haugen M, Brantsaeter AL, Trostad L, et al. Vitamin D supplementation and reduced risk of preeclampsia in nulliparous women. *Epidemiology* 2009;20:720–6.

26. Brantsaeter AL, Haugen M, Samuelsen SO, et al. A dietary pattern characterized by high intake of vegetables, fruits, and vegetable oils is associated with reduced risk of preeclampsia in nulliparous pregnant Norwegian women. *J Nutr* 2009;139:1162–8.

27. Joint FAO/WHO working group report on drafting for the evaluation of probiotics in food. London, Ontario, Canada, 2002. http://www.who.int/fsafedyn/fs_management/en/probiotic_guidelines.pdf

28. Reid G, Chakrabarty D, Erb J, et al. Use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. *Int J Food Microbiol* 2001;65:279–86.

29. Reid G, Burton J, Hammond JA, et al. Nucleic acid-based diagnosis of bacterial vaginosis and improved management using probiotic lactobacilli. *J Med Food* 2004;7:223–8.

30. Yeganeh M, Watson CS, Martins A, et al. Effect of Lactobacillus rhamnosus GR-1 supernatant and fetal sex on lipopolysaccharide-induced cytokine and prostaglandin-regulating enzymes in human placental trophoblast cells: implications for treatment of bacterial vaginosis and prevention of preterm labor. *Am J Obstet Gynecol* 2009;200:532.e1–532.e8.

31. Bloise E, Tomcic M, Novembri R, et al. Heat-killed Lactobacillus rhamnosus GG modulates uroepithel and cytokine release in primary trophoblastic cells. *Placenta* 2010;31:E87–72.

32. van Baarlen P, Troost F, van der Meer C, et al. 2010;31:867–72.

33. van Baarlen P, Troost F, van der Meer C, et al. Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. *Proceedings of the National Academy of Sciences of the United States of America* 2016;113(52):E8692–8697.

34. Lorea Baroja M, Kirjavainen PV, Hemmat S, et al. Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients. *Clin Exp Immunol* 2007;149:470–9.

35. Brantsaeter AL, Myhre R, Haugen M, et al. Intake of probiotic food and risk of preeclampsia in primiparous women: the Norwegian Mother and Child Cohort Study. *Am J Epidemiol* 2011;174:807–15.

36. Myhre R, Brantsaeter AL, Myking S, et al. Intake of probiotic food and risk of spontaneous preterm delivery. *Am J Clin Nutr* 2011;93:151–7.

37. Magnus P, Ingemarsson I, Haug K, et al. Coach profile: the Norwegian Mother and Child Cohort Study (MoBa). *Int J Epidemiol* 2006;35:1146–50.
62. Ide M, Papapanou PN. Epidemiology of association between maternal periodontal disease and adverse pregnancy outcomes--systematic review. J Clin Periodontal 2013;40(Suppl 14):S181–94.
63. Amarasekara R, Jayasekara RW, Senanayake H, et al. Microbiome of the placenta in pre-eclampsia supports the role of bacteria in the multifactorial cause of pre-eclampsia. J Obstet Gynaecol Res 2015;41:662–9.
64. Lye HS, Kuan CY, Ewe JA, et al. The improvement of hypertension by probiotics: effects on cholesterol, diabetes, renin, and phytoestrogens. Int J Mol Sci 2009;10:3755–75.
65. Agerholm-Larsen L, Raben A, Haulrik N, et al. Effect of 8 week intake of probiotic milk products on risk factors for cardiovascular diseases. Eur J Clin Nutr 2000;54:288–97.
66. Aihara K, Kajimoto O, Hirata H, et al. Effect of powdered fermented milk with Lactobacillus helveticus on subjects with high-normal blood pressure or mild hypertension. J Am Coll Nutr 2005;24:257–65.
67. Nilsen RM, Vollset SE, Gjessing HK, et al. Self-selection and bias in a large prospective pregnancy cohort in Norway. Paediatr Perinat Epidemiol 2009;23:597–608.
68. Nilsen SM, Krostad S, Holmen TL, et al. Adolescents’ health-related dietary patterns by parental socio-economic position, the Nord-Trøndelag Health Study (HUNT). Eur J Public Health 2010;20:299–305.
69. Brandhagen M, Lissner L, Brantsaeter AL, et al. Breast-feeding in relation to weight retention up to 36 months postpartum in the Norwegian Mother and Child Cohort Study: modification by socio-economic status? Public Health Nutr 2014;17:1514–23.
70. Yang S, Li W, Challis JR, et al. Probiotic Lactobacillus rhamnosus GR-1 supernatant prevents lipopolysaccharide-induced preterm birth and reduces inflammation in pregnant CD-1 mice. Am J Obstet Gynecol 2014;211:44.e1–44.e12.
71. Daskalakis GJ, Karambelas AK. Vaginal Probiotic Administration in the Management of Preterm Premature Rupture of Membranes. Fetal Diagn Ther 2017;42.
72. Marteau P, Shanahan F. Basic aspects and pharmacology of probiotics: an overview of pharmacokinetics, mechanisms of action and side-effects. Best Pract Res Clin Gastroenterol 2003;17:725–40.
73. Vesia T, Pochart P, Marteau P. Pharmacokinetics of Lactobacillus plantarum NCIMB 8826, Lactobacillus fermentum KLD, and Lactococcus lactis MG 1363 in the human gastrointestinal tract. Aliment Pharmacol Ther 2000;14:823–8.
Women taking probiotics during pregnancy might have lower pre-eclampsia and premature birth risk

*But timing may be crucial, findings suggest*

Probiotics taken during pregnancy might help lower the risks of pre-eclampsia and premature birth, suggests observational research in the online journal *BMJ Open*. But timing may be crucial, the findings indicate.

Pre-eclampsia, a condition in which the mother's body mounts an exaggerated inflammatory response, affects up to 8 percent of all pregnancies, and can lead to severe complications for both mother and baby.

Premature birth (before 37 weeks) is a leading cause of illness and disability among the children born, affecting nearly one in 10 births in the US.

A growing body of evidence suggests that the mother's diet influences the outcome of pregnancy. And previous research has suggested that probiotics--live bacteria and yeasts thought to promote good health--might reduce certain complications of pregnancy.

To find out whether the timing of intake might be influential, the researchers used data on more than 70,000 pregnancies from the Norwegian Mother and Child Cohort Study (MoBa).

As part of the MoBa study, mums-to-be provided information on their diet, lifestyle, medical history, and other relevant background factors at 15, 22, and 30 weeks of pregnancy.

At 15 and 30 weeks, the questions included additional information on intake of different milk products containing probiotic bacteria before and during their pregnancy.

Nearly one in four (just over 23%; 6502) women said they had consumed probiotic milk products before their pregnancy; more than a third (over 37%; 11,221) had done so during early pregnancy; and a similar proportion (just over 32%; 12,784) had done so late on.

Intake of probiotic milk products was more common among older, more affluent and better educated women, who were pregnant for the first time.

Among the 37,050 women included in the pre-eclampsia analysis, the condition was diagnosed in one in 20 (5%; 1851). In 550 of these cases, it was severe. Probiotic intake was associated with a 20 percent lower risk of the condition, but only during late pregnancy.

And when differences between the severity of pre-eclampsia were looked at separately this association was significant only for those whose condition was severe.

Among the 34,458 women included in the premature birth analysis, 2858 babies were born early, some 1795 of which were spontaneous premature births, and 1065 of which were iatrogenic--in other words, caused by the consequences of medical treatment.

A significant association emerged between probiotic intake during early pregnancy and an 11 percent lower risk of premature birth, rising to 27 percent for preterm birth late in the pregnancy.

The amount of probiotic consumed didn't seem to make any difference, the findings showed.
This is an observational study, so no firm conclusions can be drawn about cause and effect, nor were the researchers able to account for strain viability or shelf life, both of which may have influenced the findings. Further research is required, they emphasise.

Nevertheless, they conclude: “If future randomised controlled studies support a protective effect of probiotic consumption on reduced risk of pre-eclampsia and preterm delivery, recommending [it] would be a promising public health measure to prevent these adverse pregnancy outcomes.”